Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold

Go back to Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold
Sel-Leb Marketing, Inc. (NASDAQ: SELB) Delayed: 2.37 --0 (-0%)
Previous Close $2.37    52 Week High $24.54 
Open $2.40    52 Week Low $10.26 
Day High $2.52    P/E N/A 
Day Low $2.32    EPS $0.00 
Volume 958,576